tiprankstipranks
Trending News
More News >
American Healthcare REIT, Inc. (AHR)
NYSE:AHR
US Market

American Healthcare REIT, Inc. (AHR) AI Stock Analysis

Compare
225 Followers

Top Page

AHR

American Healthcare REIT, Inc.

(NYSE:AHR)

Select Model
Select Model
Select Model
Neutral 65 (OpenAI - 5.2)
Rating:65Neutral
Price Target:
$56.00
▲(6.93% Upside)
Action:ReiteratedDate:03/02/26
The score is driven primarily by improving financial trajectory (revenue/cash flow and apparent deleveraging) and strong technical momentum. These positives are tempered by a very expensive valuation (high P/E, modest yield) and financial statement reliability/stability concerns, despite supportive 2026 guidance from the latest earnings call.
Positive Factors
Same-store NOI Growth
Sustained double-digit same-store NOI growth across multiple quarters signals durable operational momentum in senior housing and related segments. Consistent NOI expansion reflects pricing power, occupancy gains and operating leverage that support predictable rental cash flows and normalized FFO over the medium term.
Acquisitions & Pipeline
Aggressive, accretive acquisition activity and a multi-hundred-million dollar pipeline expand scale and geographic diversification, bolstering revenue base and same-store growth potential. A sustained, disciplined acquisition program can meaningfully lift normalized FFO and create structural growth optionality over 2–6 months and beyond.
Improving Cash Generation
A clear shift to consistently positive free cash flow enhances the company's ability to fund distributions, de-lever, and invest without excessive external financing. Strengthened cash conversion improves financial flexibility and resilience to industry cycles, supporting sustainable operations and investment over the medium term.
Negative Factors
Profitability Volatility
Historic multi-year net losses followed by an abrupt 2025 profitability spike — paired with inconsistent margin reporting — undermines confidence in earnings sustainability. This volatility complicates forecasting of normalized FFO and the reliability of cash available for distributions and reinvestment over the medium term.
Abrupt Debt Reporting Shift
A sudden, large reduction or reclassification of reported debt in 2025 creates uncertainty about true leverage and trend quality. If driven by one-time settlements or accounting moves, leverage ratios may be misleading, complicating credit assessment and long-term solvency analysis until disclosures clarify the change.
Dilution Risk from Large ATM
A sizable at-the-market equity facility materially increases the potential for equity issuance to fund acquisitions or repay debt. While it provides optionality, heavy use would dilute per-share NFFO and distributions, creating a structural overhang on per-share metrics and long-term investor returns if capital deployment is frequent.

American Healthcare REIT, Inc. (AHR) vs. SPDR S&P 500 ETF (SPY)

American Healthcare REIT, Inc. Business Overview & Revenue Model

Company DescriptionFormed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value. The company benefits from a fully integrated management platform comprised of more than one hundred experienced and skilled professionals, many of whom have worked together since 2006 and have successfully invested in and managed healthcare real estate through multiple market cycles. The management team has a proven track record, deep industry relationships and unparalleled insight into each of the company's assets having built and nurtured the company's international portfolio since its original property acquisition in 2014. The strength of the management team, coupled with the quality of the assets, has American Healthcare REIT poised to capitalize on compelling growth driven by powerful demographic trends. With its 19 million-square-foot, 312-building portfolio of medical office buildings, senior housing communities, skilled nursing facilities and integrated senior health campuses diversified across 36 states and the United Kingdom, the tri-party transaction was a critical step in ideally positioning American Healthcare REIT for a future public listing or IPO on a national stock exchange at the most opportune time. By listing the company's shares on a national exchange, we believe the company will gain greater access to attractive capital that will fuel future growth, broaden our investor base and also provide liquidity to our fellow stockholders. American Healthcare REIT, Inc. operates as a subsidiary of Griffin Capital Company, LLC.
How the Company Makes MoneyAHR generates revenue primarily through rental income from its portfolio of healthcare properties leased to various tenants, including healthcare providers and operators. The company's revenue model is based on long-term leases, which typically provide stable and predictable cash flows. Key revenue streams include base rental payments, percentage rents, and reimbursement for property operating expenses. Additionally, AHR may benefit from property appreciation and strategic acquisitions. Partnerships with healthcare operators and providers can enhance occupancy rates and tenant stability, further contributing to its earnings.

American Healthcare REIT, Inc. Earnings Call Summary

Earnings Call Date:Feb 26, 2026
(Q4-2025)
|
% Change Since: |
Next Earnings Date:May 18, 2026
Earnings Call Sentiment Positive
The call conveyed strong operational momentum and financial results: double-digit same-store NOI growth across the portfolio in 2025, significant NFFO-per-share growth (22% YoY), active accretive acquisition activity (~$950M in 2025) and constructive 2026 guidance (NFFO $1.99–$2.05). Management emphasized continuity of strategy and several durable tailwinds (occupancy gains, improved payer mix, margin expansion, limited new supply). Key risks discussed were a measured deceleration in same-store growth from 2025 highs to 2026 guidance ranges, early-stage rollout of revenue-management initiatives, increased transaction competition and certain execution/leverage caveats (unsettled forward equity). On balance, the positive operational and capital markets execution substantially outweigh the manageable risks.
Q4-2025 Updates
Positive Updates
Strong Same-Store NOI Performance
Total portfolio same-store NOI growth of 11.8% in Q4 2025 and 14.2% for full-year 2025, marking a second consecutive year of double-digit same-store NOI growth.
Trilogy Segment Outperformance
Trilogy same-store NOI +14.0% in Q4 and +18.4% for full-year 2025; same-store occupancy reached 90.6% (up ~275 basis points YoY); Medicare/Medicare Advantage mix improvements delivered ~220 basis points of quality-mix improvement.
SHOP Segment Leading Growth
SHOP same-store NOI +24.6% in Q4 and +25.2% for full-year 2025; same-store occupancy ~90.6% (up ~290 basis points YoY); SHOP delivered the strongest portfolio growth and is expected to lead in 2026.
Margin Expansion and Operating Leverage
NOI margin expansion: Trilogy margins expanded ~130 basis points and SHOP margins expanded ~280 basis points in 2025 vs. 2024; management cited high operating leverage as occupancies rose toward ~90%.
Strong NFFO Results and Guidance
Normalized FFO (NFFO) of $0.46 per diluted share in Q4 and $1.72 per diluted share for FY2025 (+22% YoY NFFO per share growth). 2026 NFFO guidance of $1.99–$2.05 per diluted share (implying another year of double-digit NFFO per share growth).
2026 Same-Store NOI Guidance
Company guidance for 2026 total portfolio same-store NOI growth of 7%–11% with segment ranges: Trilogy 8%–12%, SHOP 15%–19%, Outpatient Medical 0%–2%, Triple-Net Leased 2%–3%.
Active and Accretive Capital Deployment
Closed over $950 million of new investments in 2025 (including ~$665 million closed in Q4). Early 2026 closings of ~$117.5 million and a pipeline of over $230 million; acquisitions largely relationship-sourced and targeted at higher-acuity and newer assets.
Balance Sheet and Capital Markets Execution
Improved leverage (debt-to-EBITDA improved nearly a full turn in 2025); reported net debt-to-EBITDA of 3.4x entering 2026 (excluding ~$287 million of unsettled forward agreements). Opportunistic equity issuance (ATM and November follow-on) used to fund acquisitions and development.
Platform & Development Advantages
Operating portfolio (Trilogy + SHOP) contributes ~76.9% of consolidated cash NOI; Trilogy development/expansion pipeline prioritized to generate incremental yields with limited market risk; new supply remains historically low (<1% deliveries), supporting long-term demand/supply dynamics.
Revenue Management & Operator Alignment
Piloting revenue management tools (originating from Trilogy) across SHOP operators to capture pricing power and improve RevPOR; management alignment via LTIP and equity-based incentives to share platform improvements.
Negative Updates
Leadership Transition Uncertainty
Interim CEO appointment with founder Jeff Hanson stepping in full-time while CEO Danny is on medical leave. Danny is recovering and engaged, but timing for return remains uncertain — introduces short-term leadership transition risk despite management's emphasis on continuity.
Guidance Shows Deceleration vs. 2025
2026 same-store NOI guidance (7%–11% total) and segment ranges (Trilogy 8%–12%, SHOP 15%–19%) imply deceleration from 2025 full-year results (total portfolio same-store NOI 14.2%; SHOP +25.2%; Trilogy +18.4%).
Revenue Management Early-Stage
Revenue management rollout is in pilot stages; management has not provided quantifiable results yet — potential upside is unproven at scale across operators.
Increased Competition and Cap Rate Compression
Management noted rising competition for SHOP transactions from other REITs and private equity and observed pricing in recent buys around high-5% to low-6% initial yields, stabilizing in the 7% range — cap rate compression could limit future acquisition returns.
Operational Execution Risk on Undermanaged Assets
A meaningful portion of recent acquisitions were undermanaged or underoccupied (value-add), requiring operator turnarounds; success depends on execution and timing of occupancy improvements.
Leverage Metric Caveat
Reported net debt-to-EBITDA (3.4x) excludes approximately $287 million of unsettled forward equity agreements — leverage may be understated until settlements complete.
Seasonality and Public-Health Risks
Q1 last year was meaningfully impacted by flu (higher move-outs despite strong move-ins). Management cautioned seasonality/public-health risks could affect early-2026 occupancy if severe outbreaks recur.
Reimbursement & Payer Uncertainty
CMS and Medicare/Medicare Advantage reimbursement dynamics remain a potential headwind if rates or contract discounts evolve unfavorably; company expects Medicare-related mix benefits but policy changes remain a risk.
Triple-Net Hospital Coverage Volatility
Sequential decline in hospital coverage noted in the triple-net portfolio (specific hospital tenant coverage variability), creating some quarter-to-quarter volatility, although tenant remains investment-grade and committed to the facility.
Company Guidance
AHR's 2026 guidance calls for NFFO of $1.99–$2.05 per diluted share (implying another year of double‑digit NFFO/share growth vs. 2025 NFFO of $1.72, +22% YoY) and consolidated same‑store NOI growth of 7%–11%; segment guidance is Trilogy +8%–12%, SHOP +15%–19%, Outpatient Medical 0%–2% and Triple‑Net Leased 2%–3%. The outlook only includes the $117.5M of 2026 acquisitions closed to date (not the >$230M of awarded pipeline), and the company enters 2026 with net debt/EBITDA of 3.4x (excluding ~ $287M of unsettled forward equity); it follows a 2025 year that delivered total portfolio same‑store NOI +14.2% (Q4 +11.8%), Trilogy same‑store NOI +18.4% (Q4 +14%) and SHOP same‑store NOI +25.2% (Q4 +24.6%), with Trilogy and SHOP same‑store occupancy ~90.6% (up ~275–290 bps YoY).

American Healthcare REIT, Inc. Financial Statement Overview

Summary
Steady multi-year revenue growth and improving operating/free cash flow support fundamentals, and leverage trends appear to improve into 2024–2025. Offsetting this, profitability was inconsistent with net losses in 2021–2024, and 2025 includes data-consistency red flags (margin and debt figures) that reduce confidence in the latest step-change improvement.
Income Statement
56
Neutral
Revenue has grown steadily from 2020–2024 (with positive growth each year from 2021 onward), supporting improving scale. Profitability, however, has been volatile: the company reported net losses from 2021–2024, before a sharp swing to strong profitability in 2025. The 2025 margin figures appear inconsistent (gross profit and EBITDA are far larger than revenue), which reduces confidence in the quality/interpretability of the latest-year margin profile. Overall, improving top-line trajectory and a major 2025 rebound are positives, but earnings stability is a clear historical weakness.
Balance Sheet
63
Positive
Leverage improved meaningfully over time, with debt-to-equity declining from elevated levels in 2022–2023 to a moderate level in 2024, and reported total debt dropping to zero in 2025—this is a major strengthening if accurate. Equity also increased versus 2023, improving balance-sheet cushioning. The key weakness is historical leverage (notably 2022–2023) and the abrupt 2025 debt shift, which is unusual and warrants caution when interpreting trend quality.
Cash Flow
61
Positive
Operating cash flow is consistently positive in most years and improved into 2024–2025, with free cash flow turning solidly positive in 2024 and remaining strong in 2025. Free cash flow growth was very strong in 2024, and 2025 shows free cash flow roughly matching net income, indicating improved cash conversion. Weak spots include negative free cash flow in 2021 and 2023 and uneven coverage of obligations in earlier years, highlighting prior volatility in cash generation.
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.26B2.07B1.86B1.62B1.26B
Gross Profit39.69M416.77M356.83M335.97M182.01M
EBITDA321.98M315.48M324.26M233.76M159.43M
Net Income69.81M-37.81M-71.47M-81.30M-47.79M
Balance Sheet
Total Assets5.43B4.49B4.58B4.79B4.58B
Cash, Cash Equivalents and Short-Term Investments114.84M76.70M43.45M65.05M81.60M
Total Debt1.59B1.87B3.02B2.83B2.50B
Total Liabilities2.07B2.18B3.12B3.14B2.75B
Stockholders Equity3.32B2.26B1.27B1.40B1.58B
Cash Flow
Free Cash Flow165.88M84.15M-1.26M76.25M-61.78M
Operating Cash Flow294.44M176.09M98.53M147.77M17.91M
Investing Cash Flow-1.08B-8.73M9.40M-118.58M-138.65M
Financing Cash Flow817.50M-134.74M-129.06M-42.92M94.11M

American Healthcare REIT, Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price52.37
Price Trends
50DMA
48.96
Positive
100DMA
47.77
Positive
200DMA
43.11
Positive
Market Momentum
MACD
1.23
Negative
RSI
60.40
Neutral
STOCH
29.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AHR, the sentiment is Positive. The current price of 52.37 is above the 20-day moving average (MA) of 51.25, above the 50-day MA of 48.96, and above the 200-day MA of 43.11, indicating a bullish trend. The MACD of 1.23 indicates Negative momentum. The RSI at 60.40 is Neutral, neither overbought nor oversold. The STOCH value of 29.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AHR.

American Healthcare REIT, Inc. Risk Analysis

American Healthcare REIT, Inc. disclosed 79 risk factors in its most recent earnings report. American Healthcare REIT, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

American Healthcare REIT, Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
79
Outperform
$8.93B25.539.21%3.56%59.25%88.37%
74
Outperform
$14.03B24.4711.79%6.11%13.50%31.56%
70
Outperform
$4.20B28.759.85%4.73%8.04%9.20%
70
Outperform
$5.15B32.095.59%6.47%8.12%75.95%
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
65
Neutral
$9.95B125.172.50%2.10%11.81%
64
Neutral
$6.49B-26.11-5.04%6.56%-6.59%33.35%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AHR
American Healthcare REIT, Inc.
52.37
22.63
76.09%
NHI
National Health Investors
86.75
15.99
22.60%
OHI
Omega Healthcare
47.46
12.31
35.04%
SBRA
Sabra Healthcare REIT
20.42
4.40
27.46%
HR
Healthcare Realty Trust
18.59
2.87
18.22%
CTRE
CareTrust REIT
40.01
14.32
55.73%

American Healthcare REIT, Inc. Corporate Events

Business Operations and StrategyPrivate Placements and Financing
American Healthcare REIT Launches New $1.75 Billion ATM Program
Positive
Feb 27, 2026

On February 27, 2026, American Healthcare REIT, Inc. and its operating partnership entered into a new at-the-market equity offering sales agreement with a syndicate of major investment banks, enabling the company to sell up to $1.75 billion of common stock from time to time. Concurrently, the company terminated its prior ATM program, which still had about $230.1 million of unsold capacity, and set agent commissions at up to 2% of gross sales proceeds, with flexibility for negotiated, block, and exchange-based transactions.

The structure also allows for forward sale agreements with designated banks acting as forward purchasers, under which shares may be borrowed and sold to hedge forward exposure, with pricing adjusted for interest and expected dividends. The company plans to contribute net proceeds from any issuances and forward settlements to its operating partnership for units redeemable into common stock, to be used for general corporate purposes such as debt repayment, working capital, capital expenditures, and potential future investments, enhancing balance-sheet flexibility and funding optionality.

The most recent analyst rating on (AHR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.

Business Operations and StrategyFinancial Disclosures
American Healthcare REIT Reports Strong Q4 and 2025 Results
Positive
Feb 26, 2026

American Healthcare REIT on February 26, 2026 reported GAAP net income attributable to controlling interest of $10.8 million, or $0.06 per diluted share, for the fourth quarter of 2025 and $69.8 million, or $0.42 per diluted share, for full-year 2025, alongside Normalized FFO of $0.46 and $1.72 per diluted share for the quarter and year, respectively. The company posted total portfolio same-store NOI growth of 11.8% in the fourth quarter and 14.2% for 2025, driven by its integrated senior health campuses and senior housing operating properties, which delivered same-store NOI gains exceeding 14% for the quarter and 18% for the year.

In 2025 AHR invested over $950 million in new assets across its ISHC and SHOP segments and sold two non-core properties for $3.9 million, while subsequent to year-end it acquired five additional SHOP assets for about $117.5 million in California and Missouri. As of December 31, 2025, the REIT reported a $178 million in-process development and expansion pipeline, total consolidated indebtedness of $1.54 billion, liquidity of approximately $1.14 billion and an improved Net Debt-to-Annualized Adjusted EBITDA ratio of 3.4x, underscoring a balance of aggressive growth in senior care real estate with a moderately leveraged balance sheet.

The most recent analyst rating on (AHR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.

Business Operations and StrategyExecutive/Board Changes
American Healthcare REIT Names Interim CEO During Medical Leave
Neutral
Feb 4, 2026

On February 4, 2026, American Healthcare REIT disclosed that Chief Executive Officer and President Danny Prosky took a medical leave effective February 3, 2026, with Board Chairman Jeffrey T. Hanson stepping in as interim CEO and president to maintain operational continuity alongside the established leadership team. The company emphasized its seasoned executives and ongoing commitment to its strategic objectives, underscoring confidence in uninterrupted operations despite the temporary leadership change.

The most recent analyst rating on (AHR) stock is a Buy with a $55.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.

Dividends
American Healthcare REIT Declares Q4 2025 Distribution
Positive
Dec 16, 2025

On December 16, 2025, American Healthcare REIT, Inc. announced that its board of directors declared a quarterly distribution of $0.25 per share for the fourth quarter of 2025, payable in cash on or about January 16, 2026, to shareholders of record as of December 31, 2025. This distribution reflects an annualized rate of $1.00 per share, indicating the company’s ongoing commitment to providing returns to its investors, which may enhance its attractiveness in the healthcare real estate investment sector.

The most recent analyst rating on (AHR) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on American Healthcare REIT, Inc. stock, see the AHR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 02, 2026